Slayback Pharma Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SLAYBACK PHARMA LLC, and what generic alternatives to SLAYBACK PHARMA LLC drugs are available?
SLAYBACK PHARMA LLC has thirteen approved drugs.
There are three US patents protecting SLAYBACK PHARMA LLC drugs.
Summary for Slayback Pharma Llc
US Patents: | 3 |
Tradenames: | 13 |
Ingredients: | 13 |
NDAs: | 13 |
PTAB Cases with Slayback Pharma Llc as petitioner: | See PTAB cases with Slayback Pharma Llc as petitioner |
Drugs and US Patents for Slayback Pharma Llc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Slayback Pharma Llc | TESTOSTERONE CYPIONATE | testosterone cypionate | SOLUTION;INTRAMUSCULAR | 216318-001 | Jun 2, 2022 | DISCN | Yes | No | 11,642,355 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Slayback Pharma Llc | LOTEPREDNOL ETABONATE | loteprednol etabonate | GEL;OPHTHALMIC | 213956-001 | Nov 29, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Slayback Pharma Llc | ICATIBANT ACETATE | icatibant acetate | INJECTABLE;SUBCUTANEOUS | 211501-001 | Sep 1, 2020 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Slayback Pharma Llc | TOFACITINIB CITRATE | tofacitinib citrate | SOLUTION;ORAL | 216878-001 | Sep 25, 2023 | AA | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Slayback Pharma Llc | OMEGA-3-ACID ETHYL ESTERS | omega-3-acid ethyl esters | CAPSULE;ORAL | 211345-001 | Dec 7, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.